Cargando…
Mucosal and transdermal vaccine delivery strategies against COVID-19
The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123923/ https://www.ncbi.nlm.nih.gov/pubmed/33993417 http://dx.doi.org/10.1007/s13346-021-01001-9 |
_version_ | 1783693060170842112 |
---|---|
author | Kumar, Ashwini Kumar, Awanish |
author_facet | Kumar, Ashwini Kumar, Awanish |
author_sort | Kumar, Ashwini |
collection | PubMed |
description | The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-19 vaccines. Though the route of administration for the majority of these vaccines has been the intramuscular route (invasive), some laboratories are developing formulations intended for transmucosal and transcutaneous (non-invasive) administration, which are in the early phases of pre-clinical and clinical development. This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-8123923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-81239232021-05-17 Mucosal and transdermal vaccine delivery strategies against COVID-19 Kumar, Ashwini Kumar, Awanish Drug Deliv Transl Res Technical Report The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-19 vaccines. Though the route of administration for the majority of these vaccines has been the intramuscular route (invasive), some laboratories are developing formulations intended for transmucosal and transcutaneous (non-invasive) administration, which are in the early phases of pre-clinical and clinical development. This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-05-15 2022 /pmc/articles/PMC8123923/ /pubmed/33993417 http://dx.doi.org/10.1007/s13346-021-01001-9 Text en © Controlled Release Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Technical Report Kumar, Ashwini Kumar, Awanish Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title | Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title_full | Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title_fullStr | Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title_full_unstemmed | Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title_short | Mucosal and transdermal vaccine delivery strategies against COVID-19 |
title_sort | mucosal and transdermal vaccine delivery strategies against covid-19 |
topic | Technical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123923/ https://www.ncbi.nlm.nih.gov/pubmed/33993417 http://dx.doi.org/10.1007/s13346-021-01001-9 |
work_keys_str_mv | AT kumarashwini mucosalandtransdermalvaccinedeliverystrategiesagainstcovid19 AT kumarawanish mucosalandtransdermalvaccinedeliverystrategiesagainstcovid19 |